17 results on '"Roche, Nicolas"'
Search Results
2. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review
- Author
-
Martin,Clémence, Burgel,Pierre-Régis, and Roche,Nicolas
- Subjects
International Journal of Chronic Obstructive Pulmonary Disease - Abstract
Clémence Martin,1,2 Pierre-Régis Burgel,1,2 Nicolas Roche1,2 1AP-HP Centre, Hôpital Cochin, Service de Pneumologie, Paris, France; 2Université de Paris, Institut Cochin, INSERM UMR 1016, Paris, FranceCorrespondence: Nicolas RocheService de Pneumologie, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, Paris, F-75014, FranceTel +33 1 58 41 21 53Fax +33 1 58 41 22 60Email nicolas.roche@aphp.frAbstract: Current pharmacological treatments for chronic obstructive pulmonary disease (COPD) are mostly limited to inhaled bronchodilators and corticosteroids. Azithromycin can contribute to exacerbation prevention. Roflumilast, a phosphodiesterase (PDE) 4 inhibitor administered orally, also prevents exacerbations in selected patients with chronic bronchitis, recurrent exacerbations, severe airflow limitation and concomitant therapy with long-acting inhaled bronchodilators. This outcome likely results from anti-inflammatory effects since PDE4 is expressed by all inflammatory cell types involved in COPD. The use of this agent is, however, limited by side-effects, particularly nausea and diarrhea. To address remaining unmet needs and enrich therapeutic options for patients with COPD, inhaled dual PDE3/4 inhibitors have been developed, with the aim of enhancing bronchodilation through PDE3 inhibition and modulating inflammation and mucus production though PDE4 inhibition, thus producing a potentially synergistic effect on airway calibre. Experimental preclinical data confirmed these effects in vitro and in animal models. At present, RPL554/ensifentrine is the only agent of this family in clinical development. It decreases sputum markers of both neutrophilic and eosinophilic inflammation in patients with COPD. Clinical Phase II trials confirmed its bronchodilator effect and demonstrated clinically meaningful symptom relief and quality of life improvements in these patients. The safety profile appears satisfactory, with less effects on heart rate and blood pressure than salbutamol and no other side effect. Altogether, these data suggest that ensifentrine could have a role in COPD management, especially in addition to inhaled long-acting bronchodilators with or without corticosteroids since experimental studies suggest potentiation of ensifentrine effects by these agents. However, results from ongoing and future Phase III studies are needed to confirm both beneficial effects and favourable safety profile on a larger scale and assess other outcomes including exacerbations, lung function decline, comorbidities and mortality.Keywords: COPD, phosphodiesterase inhibitors, bronchodilation, inflammation, mucus, epithelium
- Published
- 2021
3. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study
- Author
-
Dalon,Faustine, Roche,Nicolas, Belhassen,Manon, Nolin,Maëva, Pegliasco,Hervé, Deslée,Gaëtan, Housset,Bruno, Devillier,Philippe, Van Ganse,Eric, PELyon, Pharmacoepidemiologie, Lyon, Mucoviscidose et bronchopathies chroniques : biopathologie et phénotypes cliniques (EA 2511), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), Hôpital Européen de Marseille (HEM), Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL), Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Foch [Suresnes], Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de Médecine Respiratoire [HCL - Hôpital de la Croix Rousse, Lyon], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Aix-Marseille Université - Institut universitaire de technologie (IUT AMU), Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Reims Champagne-Ardenne (URCA), Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), and dormoy, valerian
- Subjects
Male ,Time Factors ,Databases, Factual ,[SDV]Life Sciences [q-bio] ,Cost-Benefit Analysis ,Muscarinic Antagonists ,International Journal of Chronic Obstructive Pulmonary Disease ,Drug Costs ,Pulmonary Disease, Chronic Obstructive ,Patient Admission ,exacerbations ,Adrenal Cortex Hormones ,COPD ,Humans ,Adrenergic beta-2 Receptor Agonists ,Lung ,ComputingMilieux_MISCELLANEOUS ,Original Research ,Aged ,Aged, 80 and over ,therapy ,health care resource use ,persistence ,Middle Aged ,Bronchodilator Agents ,[SDV] Life Sciences [q-bio] ,Treatment Outcome ,Disease Progression ,Health Resources ,Drug Therapy, Combination ,Female ,France ,Administrative Claims, Healthcare - Abstract
Faustine Dalon,1 Nicolas Roche,2 Manon Belhassen,1 Maëva Nolin,1 Hervé Pegliasco,3 Gaëtan Deslée,4 Bruno Housset,5 Philippe Devillier,6 Eric Van Ganse1,7–81Pharmacoepidemiology Department, PELyon, Lyon, France; 2Respiratory Medicine, Cochin Hospital, AP-HP and Paris Descartes University (EA2511), Sorbonne Paris Cité, Paris, France; 3Pulmonary Department, European Hospital, Marseille, France; 4Pulmonary Department, INSERM U1250, Maison Blanche University Hospital, Reims, France; 5Pulmonary Department, CHI de Créteil, University Paris Est Créteil, Créteil, France; 6Department of Airway Diseases, UPRES EA 220, Foch Hospital, Paris-Saclay University, Suresnes, France; 7EA 7425 Hesper Health Services and Performance Research, Claude-Bernard University, Lyon, France; 8Respiratory Medicine, Croix-rousse Hospital, Lyon, FranceCorrespondence: Faustine DalonPELyon, 11 Rue Guillaume Paradin, Lyon 69008, FranceTel +33 47 877 1024Fax +33 47 877 8660Email faustine.dalon@univ-lyon1.frPurposes: Following a hospitalization for COPD, dual and triple therapies were compared in terms of persistence and relations with outcomes (exacerbations, health care resource use and costs).Methods: This was a historical observational database study. All patients aged ≥45 hospitalized for COPD between 2007 and 2015 were identified in a 1/97th, random sample of French claims data. Patients receiving dual therapy within 60 days after hospitalization were compared to patients receiving triple therapy, after propensity score matching on disease severity.Results: Of the 3,089 patients hospitalized for COPD, 1,538 (49.8%) received either dual or triple therapy in the 2 months following inclusion, and 1,500 (48.6%) had at least 30 days of follow-up available; 846 (27.4%) received dual therapy, and 654 (21.2%) received triple therapy. After matching, the number of exacerbations was 2.4 per year in the dual vs 2.3 in the triple group (p=0.45). Among newly treated patients (n=206), persistence at 12 months was similar in the dual and triple groups (48% vs 41%, respectively, p=0.37). As compared to patients on dual therapy, more patients on triple therapy received oral corticosteroids (49.1 vs 40.4%, p=0.003) or were hospitalized for any reason (67%vs 55.8%, p=0.0001) or for COPD (35.3 vs 25.1%, p=0.0002) during follow-up. Cost of care was higher for patients on triple than for those on dual therapy (€11,877.1 vs €9,825.1, p=0.01).Conclusion: Following hospitalizations for COPD, patients on dual and triple therapy experienced recurrent exacerbations, limited adherence to therapies and high cost of care. Patients on triple therapy appeared more severe than those on dual therapy, as reflected by exacerbations and health care resource use.Keywords: COPD, therapy, persistence, exacerbations, health care resource use
- Published
- 2019
4. Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence
- Author
-
Usmani,Omar S, Roche,Nicolas, Jenkins,Martin, Stjepanovic,Neda, Mack,Peter, and De Backer,Wilfried
- Subjects
International Journal of Chronic Obstructive Pulmonary Disease - Abstract
Omar S Usmani,1 Nicolas Roche,2 Martin Jenkins,3 Neda Stjepanovic,4 Peter Mack,5 Wilfried De Backer6 1National Heart and Lung Institute (NHLI), Imperial College London, and Royal Brompton Hospital, London, UK; 2Respiratory Medicine, Cochin Hospital, University Paris Descartes, Paris, France; 3AstraZeneca, Cambridge, UK; 4AstraZeneca, Gothenburg, Mölndal, Sweden; 5AstraZeneca, Durham, NC, USA; 6Department of Pulmonary Medicine, Faculty of Medicine, University of Antwerp, Antwerp, BelgiumCorrespondence: Wilfried De BackerDepartment of Pulmonary Medicine, Faculty of Medicine, University of Antwerp, Lange Lozanastraat 142, Antwerp 2018, BelgiumTel +32 468 195206Email wilfried.debacker@uantwerpen.beAbstract: Metered dose inhalers (MDIs) are one of the most common device types for delivering inhaled therapies. However, there are several technical challenges in development and drug delivery of these medications. In particular, suspension-based MDIs are susceptible to suspension heterogeneity, in vitro drug–drug interactions, and patient handling errors, which may all affect drug delivery. To overcome these challenges, new formulation approaches are required. The AerosphereTM inhaler, formulated using co-suspension delivery technology, combines drug crystals with porous phospholipid particles to create stable, homogenous suspensions that dissolve once they reach the airways. Two combination therapies using this technology have been developed for the treatment of COPD: glycopyrrolate/formoterol fumarate (GFF MDI; dual combination) and budesonide/glycopyrrolate/formoterol fumarate (BGF MDI; triple combination). Here, we review the evidence with a focus on studies assessing dose delivery, lung deposition, and effects on airway geometry. In vitro assessments have demonstrated that the Aerosphere inhaler provides consistent dose delivery, even in the presence of simulated patient handling errors. Combination therapies delivered with this technology also show a consistent fine particle fraction (FPF) and an optimal particle size distribution for delivery to the central and peripheral airways even when multiple drugs are delivered via the same inhaler. Studies using gamma scintigraphy and functional respiratory imaging have demonstrated that GFF MDI is effectively deposited in the central and peripheral airways, and provides clinically meaningful benefits on airway volume and resistance throughout the lung. Overall, studies suggest that the Aerosphere inhaler, formulated using co-suspension delivery technology, may offer advantages over traditional formulations, including consistent delivery of multiple components across patient handling conditions, optimal particle size and FPF, and effective delivery to the central and peripheral airways. Future studies may provide additional evidence to further characterize the clinical benefits of these technical improvements in MDI drug delivery.Keywords: Aerosphere, BGF MDI, co-suspension delivery technology, FRI, GFF MDI, metered dose inhaler
- Published
- 2021
5. Burden and Characteristics of Severe Chronic Hypoxemia in a Real-World Cohort of Subjects with COPD
- Author
-
Zysman, Maéva, primary, Deslee, Gaëtan, additional, Perez, Thierry, additional, Burgel, Pierre-Régis, additional, Le Rouzic, Olivier, additional, Brinchault-Rabin, Graziella, additional, Nesme-Meyer, Pascale, additional, Court-Fortune, Isabelle, additional, Jebrak, Gilles, additional, Chanez, Pascal, additional, Caillaud, Denis, additional, Paillasseur, Jean-Louis, additional, and Roche, Nicolas, additional
- Published
- 2021
- Full Text
- View/download PDF
6. In Patients with Mild-to-Moderate COPD, Tobacco Smoking, and Not COPD, Is Associated with a Higher Risk of Cardiovascular Comorbidity
- Author
-
Soumagne, Thibaud, Guillien, Alicia, Roche, Nicolas, Annesi-Maesano, Isabella, Andujar, Pascal, Laurent, Lucie, Jouneau, Stéphane, Botebol, Martial, Laplante, Jean-Jacques, Dalphin, Jean-Charles, Degano, Bruno, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mucoviscidose et bronchopathies chroniques : biopathologie et phénotypes cliniques (EA 2511), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHI Créteil, CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Mutualité Sociale Agricole - Caisse de Dijon (MSA de Dijon), Caisse Centrale de la Mutualité Sociale Agricole (CCMSA), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC), Hypoxie : Physiopathologie Respiratoire et Cardiovasculaire (HP2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), COPD screening program, Novartis Pharma, Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), and Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire [Grenoble] (CHU)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)
- Subjects
[SDV]Life Sciences [q-bio] ,International Journal of Chronic Obstructive Pulmonary Disease ,respiratory tract diseases ,cardiovascular diseases ,chronic obstructive pulmonary disease ,Pulmonary Disease, Chronic Obstructive ,comorbidity ,Cross-Sectional Studies ,Risk Factors ,diabetes mellitus ,Prevalence ,Humans ,tobacco smoking ,Original Research - Abstract
Thibaud Soumagne,1 Alicia Guillien,2 Nicolas Roche,3 Isabella Annesi-Maesano,4 Pascal Andujar,5,6 Lucie Laurent,1 Stéphane Jouneau,7,8 Martial Botebol,9 Jean-Jacques Laplante,10 Jean-Charles Dalphin,1,11 Bruno Degano12,13 1Service de Pneumologie, Oncologie Thoracique et Allergologie Respiratoire, CHU de Besançon, Besançon, France; 2Equipe d’Epidémiologie Environnementale, Institute for Advanced Biosciences, Centre de Recherche UGA, INSERM U1209, CNRS UMR 5309, Grenoble, France; 3Service de Pneumologie, Groupe Hospitalier Cochin, Site Val de Grâce, AP-HP and Université Paris Descartes (EA2511), Sorbonne-Paris-Cité, Paris, France; 4Epidemiology of Allergic and Respiratory Diseases UMR-S 707 Inserm/UPMC, Université Paris 6, Paris, France; 5Centre Hospitalier Intercommunal de Créteil, Service de Pathologie Professionnelle et de l’Environnement, Créteil, France; 6Université Paris-Est Créteil, Faculté de Médecine, Créteil, France; 7Service de Pneumologie, CHU de Rennes, Rennes, France; 8Univ Rennes, CHU Rennes, Inserm, EHESP, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) – UMR-S 1085, Rennes, France; 9Fédération des Maisons de Santé Comtoises (FéMaSaC), Beure, France; 10Mutualité Sociale Agricole (MSA), Besançon, France; 11UMR CNRS Chrono Environnement, Université de Franche-Comté, Besançon, France; 12Service Hospitalier Universitaire Pneumologie Physiologie, Pôle Thorax et Vaisseaux, CHU Grenoble, Alpes, France; 13Université Grenoble Alpes, INSERM U 1042, Grenoble, FranceCorrespondence: Thibaud Soumagne Email thibaud_soumagne@live.frBackground: Comorbidities including cardiovascular diseases are very common in chronic obstructive pulmonary disease (COPD) secondary to tobacco smoking and contribute to the overall severity of the disease. In non-smoking COPD, which accounts for about 25% of COPD cases worldwide, current knowledge on the frequency and determinants of comorbidities remains scarce. The aims of the current study were to assess the frequency of major comorbidities and to evaluate their determinants in a group of non-selected patients with mild-to-moderate COPD who were exposed to organic dust (dairy farmers), to tobacco smoking, or to both, and in controls without COPD who were exposed to organic dust (dairy farmers), or to tobacco smoking, or to both, or who were without exposure.Patients and Methods: A total of 4665 subjects (2323 dairy farmers and 2342 non-farmers) including 355 patients with COPD and 4310 controls with normal spirometry were recruited through a large COPD screening program. Self-reported physician-diagnosed diseases with plausible links to COPD were recorded in this cross-sectional study.Results: Whatever the exposure, cardiovascular comorbidities were not more frequent in patients with COPD than their counterparts without airflow limitation. A higher risk of major cardiovascular comorbidities was associated with tobacco smoking and a lower risk was associated with exposure to organic dusts.Conclusion: Tobacco smoking (but not COPD) is associated with higher frequency of cardiovascular comorbidities. By contrast, being a dairy farmer exposed to organic dusts is associated with a lower frequency of the same comorbidities. This reinforces the crucial need for controlling established cardiovascular risk factors even in patients with mild-to-moderate COPD.Keywords: cardiovascular diseases, chronic obstructive pulmonary disease, comorbidity, diabetes mellitus, tobacco smoking
- Published
- 2020
7. Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
- Author
-
Voorham, Jaco, primary, Baldi, Simonetta, additional, Santoro, Luigi, additional, Kerkhof, Marjan, additional, Contoli, Marco, additional, Fabbri, Leonardo M, additional, Kerstjens, Huib AM, additional, Luis López-Campos, Jose, additional, Roche, Nicolas, additional, Singh, Dave, additional, Vogelmeier, Claus F, additional, and Price, David B, additional
- Published
- 2020
- Full Text
- View/download PDF
8. Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities
- Author
-
Perez, Thierry, primary, Deslée, Gaëtan, additional, Burgel, Pierre Régis, additional, Caillaud, Denis, additional, Le Rouzic, Olivier, additional, Zysman, Maeva, additional, Escamilla, Roger, additional, Jebrak, Gilles, additional, Chanez, Pascal, additional, Court-Fortune, Isabelle, additional, Brinchault-Rabin, Graziella, additional, Nesme-Meyer, Pascale, additional, Paillasseur, Jean-Louis, additional, and Roche, Nicolas, additional
- Published
- 2019
- Full Text
- View/download PDF
9. Pneumococcal vaccination and chronic respiratory diseases
- Author
-
Froes,Filipe, Roche,Nicolas, and Blasi,Francesco
- Subjects
International Journal of Chronic Obstructive Pulmonary Disease - Abstract
Filipe Froes,1 Nicolas Roche,2 Francesco Blasi3,4 1Chest Department, Hospital Pulido Valente, North Lisbon Hospital Center, Lisbon, Portugal; 2Department of Respiratory and Intensive Care Medicine, Cochin Hospital, Paris Descartes University, Paris, France; 3Department of Pathophysiology and Transplantation, University of Milan, 4Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS ca Granda Ospedale Maggiore Policlinico, Milan, Italy Abstract: Patients with COPD and other chronic respiratory diseases are especially vulnerable to viral and bacterial pulmonary infections, which are major causes of exacerbations, hospitalization, disease progression, and mortality in COPD patients. Effective vaccines could reduce the burden of respiratory infections and acute exacerbations in COPD patients, but what is the evidence for this? This article reviews and discusses the existing evidence for pneumococcal vaccination efficacy and its changing role in patients with chronic respiratory diseases, especially COPD. Specifically, the recent Community-Acquired Pneumonia Immunization Trial in Adults (CAPITA) showed the efficacy of pneumococcal conjugate vaccine in older adults, many of whom had additional risk factors for pneumococcal disease, including chronic lung diseases. Taken together, the evidence suggests that pneumococcal and influenza vaccinations can prevent community-acquired pneumonia and acute exacerbations in COPD patients, while pneumococcal vaccination early in the course of COPD could help maintain stable health status. Despite the need to prevent pulmonary infections in patients with chronic respiratory diseases and evidence for the efficacy of pneumococcal conjugate vaccine, pneumococcal vaccine coverage and awareness are low and need to be improved. Respiratory physicians need to communicate the benefits of vaccination more effectively to their patients who suffer from chronic respiratory diseases. Keywords: COPD, COPD exacerbation, infection, pneumococcal vaccine
- Published
- 2017
10. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
- Author
-
Vogelmeier, Claus, primary, Chapman, Kenneth, additional, Miravitlles, Marc, additional, Roche, Nicolas, additional, Vestbo, Jørgen, additional, Thach, Chau, additional, Banerji, Donald, additional, Fogel, Robert, additional, Patalano, Francesco, additional, Olsson, Petter, additional, Kostikas, Konstantinos, additional, and Wedzicha, Jadwiga, additional
- Published
- 2018
- Full Text
- View/download PDF
11. Anxiety and depression among dairy farmers: the impact of COPD
- Author
-
Guillien, Alicia, primary, Laurent, Lucie, additional, Soumagne, Thibaud, additional, Puyraveau, Marc, additional, Laplante, Jean-Jacques, additional, Andujar, Pascal, additional, Annesi-Maesano, Isabella, additional, Roche, Nicolas, additional, Degano, Bruno, additional, and Dalphin, Jean-Charles, additional
- Published
- 2017
- Full Text
- View/download PDF
12. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD
- Author
-
zysman, maeva, primary, Deslee, Gaétan, additional, caillaud, denis, additional, chanez, pascal, additional, escamilla, roger, additional, court-fortune, isabelle, additional, nesme-meyer, pascale, additional, perez, thierry, additional, paillasseur, jean-louis, additional, pinet, christophe, additional, jebrak, gilles, additional, roche, nicolas, additional, and burgel, pierre-regis, additional
- Published
- 2017
- Full Text
- View/download PDF
13. Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study
- Author
-
Dres, Martin, primary, Hausfater, Pierre, additional, Foissac, Frantz, additional, Bernard, Maguy, additional, Joly, Luc-Marie, additional, Sebbane, Mustapha, additional, Philippon, Anne-Laure, additional, Gil-Jardiné, Cédric, additional, Schmidt, Jeannot, additional, Maignan, Maxime, additional, Treluyer, Jean-Marc, additional, and Roche, Nicolas, additional
- Published
- 2017
- Full Text
- View/download PDF
14. Impact of current cough on health-related quality of life in patients with COPD
- Author
-
Deslee, Gaétan, primary, Burgel, Pierre-Regis, additional, Escamilla, Roger, additional, Chanez, Pascal, additional, Court-Fortune, Isabelle, additional, Nesme-Meyer, Pascale, additional, Brinchault-Rabin, Graziella, additional, Perez, Thierry, additional, Jebrak, Gilles, additional, Caillaud, Denis, additional, Paillasseur, Jean-Louis, additional, and Roche, Nicolas, additional
- Published
- 2016
- Full Text
- View/download PDF
15. Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease
- Author
-
Perez, Thierry, primary, Burgel, Pierre Régis, additional, Paillasseur, Jean Louis, additional, Caillaud, Denis, additional, Deslée, Gaétan, additional, Chanez, Pascal, additional, and Roche, Nicolas, additional
- Published
- 2015
- Full Text
- View/download PDF
16. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD
- Author
-
Price, David, primary, Postma, Dirkje, additional, Roche, Nicolas, additional, Colice, Gene, additional, Israel, Elliot, additional, Martin, Richard, additional, van Aalderen, Willem, additional, Grigg, Jonathan, additional, Burden, Anne, additional, Hillyer, Elizabeth, additional, von Ziegenweidt, Julie, additional, and Gopalan, Gokul, additional
- Published
- 2014
- Full Text
- View/download PDF
17. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD.
- Author
-
Postma DS, Roche N, Colice G, Israel E, Martin RJ, van Aalderen WM, Grigg J, Burden A, Hillyer EV, von Ziegenweidt J, Gopalan G, and Price D
- Subjects
- Administration, Inhalation, Adrenal Cortex Hormones adverse effects, Adrenal Cortex Hormones chemistry, Aged, Androstadienes adverse effects, Androstadienes chemistry, Anti-Bacterial Agents therapeutic use, Beclomethasone adverse effects, Beclomethasone chemistry, Disease Progression, Emergency Service, Hospital, Female, Fluticasone, Hospitalization, Humans, Lung physiopathology, Male, Middle Aged, Particle Size, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive physiopathology, Retrospective Studies, Severity of Illness Index, Smoking adverse effects, Smoking Cessation, Smoking Prevention, Time Factors, Treatment Outcome, Adrenal Cortex Hormones administration & dosage, Androstadienes administration & dosage, Beclomethasone administration & dosage, Lung drug effects, Pulmonary Disease, Chronic Obstructive drug therapy
- Abstract
Purpose: Small airway changes and dysfunction contribute importantly to airway obstruction in chronic obstructive pulmonary disease (COPD), which is currently treated with inhaled corticosteroids (ICS) and long-acting bronchodilators at Global initiative for Obstructive Lung Disease (GOLD) grades 2-4. This retrospective matched cohort analysis compared effectiveness of a representative small-particle ICS (extrafine beclomethasone) and larger-particle ICS (fluticasone) in primary care patients with COPD., Patients and Methods: Smokers and ex-smokers with COPD ≥ 40 years old initiating or stepping-up their dose of extrafine beclomethasone or fluticasone were matched 1:1 for demographic characteristics, index prescription year, concomitant therapies, and disease severity during 1 baseline year. During 2 subsequent years, we evaluated treatment change and COPD exacerbations, defined as emergency care/hospitalization for COPD, acute oral corticosteroids, or antibiotics for lower respiratory tract infection., Results: Mean patient age was 67 years, 57%-60% being male. For both initiation (n=334:334) and step-up (n=189:189) patients, exacerbation rates were comparable between extrafine beclomethasone and fluticasone cohorts during the 2 year outcome period. Odds of treatment stability (no exacerbation or treatment change) were significantly greater for patients initiating extrafine beclomethasone compared with fluticasone (adjusted odds ratio 2.50; 95% confidence interval, 1.32-4.73). Median ICS dose exposure during 2 outcome years was significantly lower (P<0.001) for extrafine beclomethasone than fluticasone cohorts (315 μg/day versus 436 μg/day for initiation, 438 μg/day versus 534 μg/day for step-up patients)., Conclusion: We observed that small-particle ICS at significantly lower doses had comparable effects on exacerbation rates as larger-particle ICS at higher doses, whereas initiation of small-particle ICS was associated with better odds of treatment stability during 2-years' follow-up.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.